Selected comments from Quidel CC
"
Second, we also expect that Savanna revenue will be immaterial in 2024 with no expected U.S. respiratory revenue contribution from Savanna in the 2024, 2025 respiratory season." Andrew Cooper: Just what’s your views on a product like Savanna in the competitive molecular kind of marketplace, how do you think about the actual kind of ability to go out and compete with that kind of mid-plex product? And what’s attractive about that platform, in particular, as you think about the path forward?
Brian Blaser: I think it’s an attractive competitive product, quite frankly, and – and to the point our challenge is menu. And my focus is getting the menu of tests on that platform as quickly as we can so that we have a competitive offering in the deal.
Conor McNamara: Great. Thanks for that color. And then just a follow-up on Savanna. You took revenues out. So you took respiratory revenue. Is the thought that if you guys do get approval for respiratory panel, you would still wait until you have multiple panels before you launch into the market? Because Brian, it sounds like that’s kind of what your commentary was leading to. Or is there – is there a chance you would still launch it in 2024 with just respiratory?
Mike Iskra: Yes. Conor, good question. So look, I think we are all absolutely clear on two things. One, the guidance we gave is around financial expectations for Savanna. Let’s not confuse that with the operational expectations. We have a very aggressive plan that move as quickly as we can, not just on respiratory, but as mentioned, STI. And as Brian mentioned, the rest of the Savanna menu which is critical. I think what we will be careful to do is set our expectations too early. But we don’t want them to confuse with this is sort of an unrelenting effort to get products approved out in the market as soon as possible.
https://www.insidermonkey.com/blog/quidelortho-corporation-nasdaqqdel-q1-2024-earnings-call-transcript-1299952/#q-and-a-session